Business Daily from THE HINDU group of publications
Wednesday, Jul 18, 2007
ePaper


News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

Industry & Economy - Economic Offences
Money & Banking - RBI & Other Central Banks
World Bank debars two Indian firms

Our Bureau

Mumbai, July 17 The World Bank has declared Delhi-based Nestor Pharmaceuticals Ltd (Nestor) and Mumbai-based Pure Pharma Ltd “ineligible” to be awarded bank-financed contracts.

Both firms were found to have engaged in “collusive practices” in connection with the bank-financed Reproductive and Child Health Project (RCHI) in India, a note from the bank said.

Allegations

Nestor has been debarred for three years, while Pure Pharma is debarred for one year. The decision to debar the two companies was based on evidence from an investigation by the World Bank’s Department of Institutional Integrity (INT) into allegations of impropriety in the procurement of pharmaceuticals under the RCHI project. This was the first case heard by the bank’s Sanctions Board, the note said.

Both Nestor Pharma and Pure Pharma did not return calls made by the paper.

Pharma industry representatives, who have participated in similar health-related projects in the past, said that such projects could run into few hundred crore worth of medicines annually. In this case, it may have comprised gynaecology drugs, birth-control products, vaccines for inoculations etc.

Evidence

The RCHI programme was designed by the Centre to help deliver medical services to vulnerable citizens, said Mr Praful Patel, World Bank’s Vice-President for South Asia.

“The actions of both companies harmed the very people this project was meant to help,” he said in the note.

The Sanctions Board, a recently constituted body inside the World Bank Group comprising external and internal members, weighed the evidence presented by INT and that provided by the firms.

It found both firms had engaged in misconduct, the note said. Mr Danny Leipziger, Vice-President of the World Bank Group and Chairman of the Bank’s Sanctions Board, said that the decision was inline with the bank’s mandate to ensure that its funds are properly utilised. “…in this case, it was found that the two firms had behaved improperly and the requisite penalties were imposed,” he said.

More Stories on : Economic Offences | RBI & Other Central Banks | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
UK business awards


Renault Design India to play bigger role
Credit Suisse sees recovery in consumer spending in H2
‘10% growth achievable in 2008-09’
Bengal emerging hub for medical tourism
Acquisition for Mangalore SEZ
Petro products sales rise 10.9% in June
Rig distinction
‘Budget estimate on direct taxes will be met’
Textile firms leverage Italian tie-ups to move up value chain
GVFL to raise Rs 300 cr by 2010
TN policy for micro, SME sectors on the anvil
SSI assn moots trade centre
Kerala ready for talks on Mullaperiyar
Rice in beer makes a heady brew for Budweiser
Panel okays site for IIT
IIT-B offers new range of programmes
Osmania offers new PG programme
A mega science city in thin air
‘Small savings decline 21% during 2006-07’
Nabard aims at direct financing to SHGs
Mobile firms ready to battle it out at TRAI open house
Guidelines on stock options computation soon
Rising rupee: Exporters look for further relief
Deluge all around
World Bank debars two Indian firms


The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line